These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 22050742)
21. Structure-functional diversity of human L-type Ca2+ channel: perspectives for new pharmacological targets. Abernethy DR; Soldatov NM J Pharmacol Exp Ther; 2002 Mar; 300(3):724-8. PubMed ID: 11861774 [TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of novel N3-substituted dihydropyrimidine derivatives as T-type calcium channel blockers and their efficacy as analgesics in mouse models of inflammatory pain. Teleb M; Zhang FX; Huang J; Gadotti VM; Farghaly AM; AboulWafa OM; Zamponi GW; Fahmy H Bioorg Med Chem; 2017 Mar; 25(6):1926-1938. PubMed ID: 28233679 [TBL] [Abstract][Full Text] [Related]
23. [Calcium antagonists of the dihydropyridine type: pharmaceutical chemistry and molecular pharmacology]. Mannhold R Pharm Unserer Zeit; 1995 Jun; 24(3):137-53. PubMed ID: 7610109 [No Abstract] [Full Text] [Related]
24. Structure-activity relationships of receptor binding of 1,4-dihydropyridine derivatives. Takahashi D; Oyunzul L; Onoue S; Ito Y; Uchida S; Simsek R; Gunduz MG; Safak C; Yamada S Biol Pharm Bull; 2008 Mar; 31(3):473-9. PubMed ID: 18310913 [TBL] [Abstract][Full Text] [Related]
27. Discovery of Michael acceptor containing 1,4-dihydropyridines as first covalent inhibitors of L-/T-type calcium channels. Aygün Cevher H; Schaller D; Gandini MA; Kaplan O; Gambeta E; Zhang FX; Çelebier M; Tahir MN; Zamponi GW; Wolber G; Gündüz MG Bioorg Chem; 2019 Oct; 91():103187. PubMed ID: 31419643 [TBL] [Abstract][Full Text] [Related]
28. The structure-activity relationship study on 2-, 5-, and 6-position of the water soluble 1,4-dihydropyridine derivatives blocking N-type calcium channels. Yamamoto T; Niwa S; Ohno S; Tokumasu M; Masuzawa Y; Nakanishi C; Nakajo A; Onishi T; Koganei H; Fujita S; Takeda T; Kito M; Ono Y; Saitou Y; Takahara A; Iwata S; Shoji M Bioorg Med Chem Lett; 2008 Sep; 18(17):4813-6. PubMed ID: 18684623 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of ATP-induced surfactant exocytosis by dihydropyridine (DHP) derivatives: a non-stereospecific, photoactivated effect and independent of L-type Ca2+ channels. Frick M; Siber G; Haller T; Mair N; Dietl P Biochem Pharmacol; 2001 May; 61(9):1161-7. PubMed ID: 11301050 [TBL] [Abstract][Full Text] [Related]
30. Structural model for phenylalkylamine binding to L-type calcium channels. Cheng RCK; Tikhonov DB; Zhorov BS J Biol Chem; 2009 Oct; 284(41):28332-28342. PubMed ID: 19700404 [TBL] [Abstract][Full Text] [Related]
31. Vascular effects of calcium channel antagonists: new evidence. Richard S Drugs; 2005; 65 Suppl 2():1-10. PubMed ID: 16398057 [TBL] [Abstract][Full Text] [Related]
32. Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. Chang CC; Cao S; Kang S; Kai L; Tian X; Pandey P; Dunne SF; Luan CH; Surmeier DJ; Silverman RB Bioorg Med Chem; 2010 May; 18(9):3147-58. PubMed ID: 20382537 [TBL] [Abstract][Full Text] [Related]
33. Comparative QSAR studies of two series of 1,4-dihydropyridines as slow calcium channel blockers. Wikel JH; Bemis KG; Kurz K; Denney ML; Main BW; Moore RA; Smith T; Shingleton L; Holland DR Drug Des Discov; 1994 Jan; 11(1):1-14. PubMed ID: 8068815 [TBL] [Abstract][Full Text] [Related]
34. 4-isoxazolyl-1,4-dihydropyridines: a tale of two scaffolds. Natale NR; Steiger SA Future Med Chem; 2014 May; 6(8):923-43. PubMed ID: 24962283 [TBL] [Abstract][Full Text] [Related]
35. Permanently charged chiral 1,4-dihydropyridines: molecular probes of L-type calcium channels. Synthesis and pharmacological characterization of methyl(omega-trimethylalkylammonium) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate iodide, calcium channel antagonists. Peri R; Padmanabhan S; Rutledge A; Singh S; Triggle DJ J Med Chem; 2000 Jul; 43(15):2906-14. PubMed ID: 10956198 [TBL] [Abstract][Full Text] [Related]
36. Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels. Yamamoto T; Niwa S; Ohno S; Onishi T; Matsueda H; Koganei H; Uneyama H; Fujita S; Takeda T; Kito M; Ono Y; Saitou Y; Takahara A; Iwata S; Shoji M Bioorg Med Chem Lett; 2006 Feb; 16(4):798-802. PubMed ID: 16309909 [TBL] [Abstract][Full Text] [Related]
37. Characterizing the 1,4-dihydropyridines binding interactions in the L-type Ca2+ channel: model construction and docking calculations. Cosconati S; Marinelli L; Lavecchia A; Novellino E J Med Chem; 2007 Apr; 50(7):1504-13. PubMed ID: 17335186 [TBL] [Abstract][Full Text] [Related]
38. Dihydropyridine-induced Ca2+ release from ryanodine-sensitive Ca2+ pools in human skeletal muscle cells. Weigl LG; Hohenegger M; Kress HG J Physiol; 2000 Jun; 525 Pt 2(Pt 2):461-9. PubMed ID: 10835047 [TBL] [Abstract][Full Text] [Related]
39. Transfer of 1,4-dihydropyridine sensitivity from L-type to class A (BI) calcium channels. Grabner M; Wang Z; Hering S; Striessnig J; Glossmann H Neuron; 1996 Jan; 16(1):207-18. PubMed ID: 8562085 [TBL] [Abstract][Full Text] [Related]
40. Synthesis, Docking Simulation, Biological Evaluations and 3D-QSAR Study of 1,4-Dihydropyridines as Calcium Channel Blockers. El-Moselhy TF; Sidhom PA; Esmat EA; El-Mahdy NA Chem Pharm Bull (Tokyo); 2017; 65(10):893-903. PubMed ID: 28966273 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]